A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Patients with HCV genotype 6 infection who have a rapid virological response to treatment are
randomised to either 24 or 48 weeks HCV treatment. Our hypothesis is that there is no
important difference in effect between the two treatment effect.